IJPSR (2023), Volume 14, Issue 10 **(Research Article)**

INTERNATIONAL JOURNAL OF PHARMACEUTICAL SCIENCES AND RESEARCH

Received on 22 February 2023; received in revised form, 05 April 2023; accepted 28 September 2023; published 01 October 2023

WITHAFERIN A: AN EXPLORATION OF TROPANE ALKALOID ASSOCIATED NEUROLOGICAL DYSFUNCTION BY CONQUERING A BETA PROTEIN

Sonu Sharma [1], Vineylather [*1], Vikram Sharma [2] and Chetan Ram [3]

Amity Institute of Pharmacy [1], Amity University, Noida - 201301, Uttar Pradesh, India.
Galgotia College of Pharmacy [2], Greater Noida - 201310, Uttar Pradesh, India.
Faculty of Pharmacy [3], SoPPHI, DIT University, Dehradun - 248009, Uttarakhand, India.

Keywords:

Withaferin A, *Substantia nigra*, Neurological disorders, Toxic neuro protein, Beta amyloid (Ab) transfected plasmidbeta, Cocaine

Correspondence to Author:
Dr. Vineylather

Professor,
Amity Institute of Pharmacy,
Amity University, Noida - 201301,
Uttar Pradesh, India.

E-mail: vlather@amity.edu

ABSTRACT: Neurological problems should be considered a major public health issue. Around 40%–70% of people exposed to HIV suffer neurological problems such as Amyotrophic lateral sclerosis (ALS), Parkinson's disease (PD), and other comparable conditions. Various neurological diseases including ALS, Alzheimer's, and Parkinson's disease are caused by amyloid-beta accumulation in extracellular regions of the brain. The *Substantia nigra's* dopaminergic neurons have been damaged in a widespread and gradual manner. The life span of HIV-infected patients has risen during this period of antiretroviral medication, resulting in increased neurocognitive impairment in around 33% of HIV entities, mainly adults. The testimony of the A inscriptions in the CNS is the most popular sight among elderly HIV patients. ART is separated from harmful duplication, but the harmful neuronal protein (Tat) is still produced, following in facilitated A phases. Furthermore, Cocaine-like drug (COC) use has been linked to HIV-related neurocognitive issues and A excretion. Withaferin A is emitted by inducing the targeting Tat and COC, we suggest Withaferin A (WA), a contemporary bifunctional fragment that acts as a neuroprotectant in the face of A neurotoxicity. In APP-transfected plasmid SH-SY5Y cells, WA lowers secreted A and reduces neurotoxicity (SH-APP). In this research, we investigated that in the availability of HIV-1 Tat which is a neurotoxin and the abusive drug COC, A secretion is enhanced in SH-APP cells. When related to normal control SH-APP cells, Luminescence microscopy tests confirm the elevated concentrations of A40 (50 ng/ml) and COC (0.1 M) in test SH-APP cells. Lower doses of WA (0.5–2 M) considerably lower A40 levels in SH-APP cells while generating no cytotoxicity, according to the dose optimization study. WA also lowers the amount of A produced by Tat and Cocaine. As a consequence, we conclude that the presence of Tat and Cocaine promotes A aggregation, but that WA is effective in eliminating hidden A and preventing subsequent neurotoxicity. This study opens up new paths for the finding of viral contamination in brain diseases. Our findings revealed that there are new levels of medicinal competence that are incompatible with neurological disorders.

INTRODUCTION: Because with the introduction of modern anti-HIV therapies, the people's global life standard that is living with HIV has increased moderately [1].

QUICK RESPONSE CODE

DOI: 10.13040/IJPSR.0975-8232.14(10).5074-86

This article can be accessed online on www.ijpsr.com

DOI link: http://doi.org/10.13040/IJPSR.0975-8232.14(10).5074-86

By WHO, the global death rate from AIDS has diminished from 1.5 billion in 2010 to 1.1 billion in 2015.

The virus life cycle and chronic use of anti-retroviral drugs were associated with continuously HIV-1 infection and neurocognitive problems [2]. Furthermore, PLWH (1.5 billion, according to the WHO, 2018) is the more severe problem of generating neurocognitive issues similar to

Parkinson's and Alzheimer's disease. Because HIV infection is associated with the generation of Alzheimer's disease, it has become a global health issue that must be addressed [3].

While neurological disorders are incurable, new drugs that are more effective and have fewer adverse effects are desperately needed to treat these mental problems. AD is a neuronal disease marked by a frequent degeneration of cognitive and memory abilities caused by an excess aggregation of amyloid-βextracellularly and neurofibrillary masses intracellularly [4].

In the brain, a buildup is noticeable in the limbic and cortical portions of the brain [3, 5]. Ghosh *et al*. (2008) found that alternate or abnormal breakage of intra-membrane APP protein leads to irregular A plaques [6]. This A buildup causes attenuate health and stability of neuronal cells, deteriorating, synaptic hopelessness [6], oxidative anxiety [7, 8], amplified dysfunction of neurons, and tenderness [7–9].

The presence of HIV-1 [10] and misused medicines exacerbated these dysfunctions caused by A buildup. We have deliberated valuable possessions of Withaferin A (WA) in the absence of several disease-related qualities, such as A, HIV-1 Tat, and the abusive drug, coc, in this object. WA is a purified energetic pharmacological component derived from Ashwagandha (ASH), which was extracted through the root extraction of a therapeutic plant that is used in Ayurvedic medicine since ancient times. WA is the first ergostane-type compound from the withanolide class to be exposed [11].

WA has antiangiogenic capabilities [12, 13], and anti-carcinogenic effects [13, 14] investigated the same quantification of kept cells with changing concentrations of WA and flow cytometry apparatus was running to analyze A1–40 stages by 48 hours of use. The appearance of A1–40 in SH-APP cells using3-doses of WA was determined using the instrument flow cytometry. Hematoxylin and eosin were used to stain 1 106 SH-APP cells.

MATERIAL AND METHOD: Sigma Aldrich provided the withaferin A (WA). (Sigma Aldrich provided the methyl thiazolyl diphenyl-tetrazolium bromide (MTT) and another chemical taken from DIPSAR (Delhi) which was paraformaldehyde. The NIH AIDS investigation and orientation program provided the B recombinant Tat protein HIV-1 clade.

Cell Culture: SH-APP, human APP751, and human neuroblastoma cells were grown in Dulbecco Eagle's standard with 10% fetal bovine serum, penicillin, 100 U/ml non-essential amino acids, and sodium pyruvate (1Mm) in 5% CO_2 at 37 °C.

Cell Feasibility Assay: The cells were coated at the concentration of 104 cells/well in 96-wells and kept at 37°C for 24 hours. WA was inserted at various concentrations to preserve the cells for 2 days. 50L of MTT solution (0.5 mg/mL) was put into every well. Dimethyl sulfoxide was used to dissolve the MTT crystals. A microplate reader was used and set at 570 nm for 3 hours to measure the absorbance of the practical cells for its identification.

We used a cell viability assay with a 0.4 % solution of Trypan Blue (T8154) deceased screening for COC and Tat toxicity studies. The cells were removed in ten microliters of the pellet that is redissolved in fresh mass media, centrifuged at 1500 rpm for 5 minutes maximum, and then mixed Trypan blue dye (10 l) in a 1:1 ratio. The cells were put on a slide that counted pre-programmed cells, and the conscious amount was calculated using a cell counter (Computerized cell counter).

Handling of Tat and COC in Sh-App Cubicles: To control the WA as a non-toxic dosage with different proportions (0.5–10 m) of WA were well-preserved in SH-APP cell lines firmly articulating humanoid APP751 cells, and when related to the normal control, the results revealed that WA decreases concealed A40 in SH-APP cells by 2 m, as shown in the image **Fig. 1A Fig. 1B**. Flow cytometry was used to determine the results, and they were found to be free from cellular noxiousness toxicity in WA.

A β Stages Quantification: A β concentrations were calculated with an ELISA kit according to the procedure. The mass media of refined cells was taken and the protease inhibitor addition was completed. Samples of the supernatant were used as the specific compounds.

The individual trial was examined in matching. Finally, flow cytometry testing was used to analyze the cells that were kept to examine intracellular Aβ40.

Flow Cytometry: In the first phase, primary A40 anti-human and secondary Fluorescein isothiocyanate (FITC) anti-rabbit antibodies were used to label SH-APP (1 106) cells. Auto fluorescence was examined on cells that had not been stained.

Later, the cell was saved with the help of a secondary antibody. For procurement, Amnis® Imaging Flow Cytometers were discarded. IDEAS® imaging program was used to examine the investigation.

Flow Cytometry:

Single-Cell: Dissimilar doses of WA were used to preserve the SH-APP cells. After 24 hours of handling, the cells were collected, washed, and quantified; comparable quantities of cubicles (1 106) remained in an Eppendorf centrifuge of 1.5 ml in 250 l. The cells were then studied using the INSPIRE program on an Amnis Imaging Flow Cytometer.

We used a magnification that was designed for all 60 interpretations. A total of 10,000 cells were analyzed for every sample. DAPI and FITC were determined using an argon laser with a power of 100 mW and a wavelength of 488 nm.

Separately, the fluorescence of FITC was calculated on channel two (507–561 nm) and the fluorescence of DAPI was analyzed on channel seven (562–596 nm).

Intensity changes on channel one saved bright field photos gathered. IDEAS program was used to calculate the total fluorescence and bright field area.

Aggregation of Beta-Amyloid through Evaluation of Immunofluorescence Staining: An immunofluorescence trial was performed due to morphology accumulation because of WA. These cells remained cultured in the microscopy slides to achieve maximum confluencyl ate treated with HIV-1T at + and Tat−WA. The supernatant was cast-off in the Next 48 h then the cells remained immovable in PFA (4%).

PFA implanted slides then immunoassay through primary antibody, taken in a ratio of (1:100) A β40 then GFP in 1:100 ratio secondary antibody. Immuno-marked segments remained seized using the Keyence microscope.

Neuronalmorphology through Immuno-fluorescence: To understand the consequences of WA, we conducted an immunofluorescence imaging trial and went through neuronal morphology outcomes.

These cells remained cultured in the microscopy slides to achieve maximum confluency later treated with HIV-1T at+ and Tat−WA. The supernatant was cast-off for the next 48hthenthecells remained immovable in PFA (4%). PFA-implanted slides were then swept away and immunostained usingMAP2 (1:100) and anti-FITC (1:100) were used as secondary antibodies.

The primary antibody, MAP2 (1:100), and the secondary antibody, anti-FITC (1:100), both seized the highlighted regions. The image scanner was used to capture the designated segments, which were then inspected using Image Scope software

Facts Examination: The trials' outcomes represent two or more independent trials. For unpaired observations, Graph Pad Prism software was used to investigate numerical implication, as well as ANOVA, chi test, and Student's t-test. The results are presented in a means SEM format.

RESULTS:

WA Drug Optimization: Analyses of an Effectiveness in SH-APP Cell Line: Various concentrations (0.5–10 m) of WA were very well in SH-APP cells, strongly expressing humanoid APP751 cell lines to regulate the non-toxic WA dose of the drug, and the results showed that WA minimizes secreted A40 in SH-APP cells by 2 m while compared to the normal control, as seen in the picture **Fig. 1A Fig. 1B**. Flow cytometry was used to evaluate the findings, and these were found to be devoid of intracellular noxiousness in WA **Fig. 1.**



FIG. 1 THE EFFECTS OF WITHAFERIN A. (A) After 48 hours of handling, the supernatants were collected after treating WA with varied dosages of WA. The byproduct was analyzed using ELISA, and we could explain the considerable reduction compared to unprocessed control samples at an optimal or minimum dose of 1.5- 2 M WA responsible for the phases of released A40. (B) The amount of WA indicated for this trial was also tested for cellular toxicity. A low quantity of WA was examined to be non-toxic in a cell toxicity test. WA had no influence on cell survival or toxicity in SH-SY5Y cells since its optimal concentration was 2 M **Fig. 2C.**





FIG. 2: $A\beta_{1-40}$ INHIBITED BY WA

The method that is reliant on the SH-APP cell line histograms of A secretion when dealing with a variable amount of WA is shown on Sheet (A). Sheet (B) shows the peaks' persistence in a single histogram, while sheet (C) demonstrates the same quantification. After that, the cells were kept with varying concentrations of WA, and flow cytometry was used to determine the A1–40 stages after 48 hours of handling. The appearance of A1–40 in SH-APP cells by treatment with 3 doses of WA was determined using flow cytometry. Hematoxylin and eosin were used to stain 1 106 SH-APP cells.



FIG. 3: (A) A BAR GRAPH DEPICTS THE MEAN STANDARD DEVIATION OF % OF MEAN FLUORESCENCE STRENGTH. (B) SINGLE-CELL PHOTOS FOR DEMONSTRATION. AFTER THAT, WE CONFIDENTLY DETECTED EXPRESSIVELY CONDENSED WITH WA UNDERSTANDING DOSAGE

Consequences of WA on the secretion of Aβ: Cells were preserved by using different doses of WA, and the supernatants were collected after 48 hours. A1–40 ELISA was used to test the supernatant and confirmed that at an optimal dose of 2 M WA, the levels of released A40 were significantly lower in control untreated samples. The cellular toxicity of the Withaferin A dosage utilized in this experiment was also investigated. The lower dosages of WA were not hazardous to cells in the cell toxicity assay. An ideal dosage of 2 M of WA did not influence cell survival or toxicity (p 0.001). (p 0.001).

Effect on Aβ synthesis in SH-APP Cells: To measure the efficacy of WA in lowering A production generated by HIV-Tat and COC, ELISA was conducted on the obtained supernatant from normal and WA-maintained SH-APP cell experiments. SH-APP cells were maintained using Tat (5–50 ng/ml) and COC (0.1–10 M) dosages. **Fig. 4** reveals that the A1–40 excretion regulation of SH-APP cells preserved with Tat was similar to that of unprocessed control cells **Fig. 4A, B**. When the true amount of Tat (50 ng/ml) was preserved with 2 M WA, the A1–40 levels dropped Fig. 4C significantly.



FIG. 4: TAT CAUSES AN ELEVATE IN A40 SECRETION. (A). As per ELISA assays of human Amyloid Beta, tat (5–50 ng/mL) dramatically enhanced secreted A1–40 in SH-APP cells. (B) A cytotoxic test was used to measure cell survival in Tat-treated materials. (C) When contrast to Tat (50 ng/mL) singly administered samples, 2M WA dramatically reduced Tat concentrations. 1 106 SH-APP cells were cultivated in 6-well for 48 hours until administered with HIV-1 Tat at different dosages and maintained at 37°C for 48 hours. The culture supernatant was filtered and processed with a protease inhibitor (1 l/ml) before employing an A1–40 ELISA (Sigma).

Using a primary antibody specific for A1–40, flow cytometry was performed to corroborate the results. When compared to the control group, the 50 ng/ml Tat dose significantly increased A levels **Fig. 1** and **2.** In a similar experimental pattern, we looked at the effect of COC and discovered an increase in A1–40 secretions **Fig. 6A, B**.

In comparison to untreated controls, 0.1 M demonstrated the most substantial increase in A1–40 secretion. When treated with 2 M WA, the effective dose of COC (0.1 M) exhibited a substantial reduction in A1–40 **Fig. 6C**. The flow cytometry experiment corroborated this pattern, showing a COC-induced elevate in A levels **Fig. 7A, B**. A1–40 specific primary antibody **Fig. 4.**

The student's t-test was used to examine the statistically significant results of data from three various studies. A cell viability analysis was undertaken using Trypan blue live dead showing to investigate the toxicity stages of numerous Tat dosages. In the following experiment, the dose for Tat administration was established based on an increase in A40 secretion, which was linked to cell survival (***p 0.001). **Fig. 5.**



FIG. 5: (A) THE HISTOGRAMS REVEAL THAT TAT (10–100 NG/ML) BOOSTS THE A1–40 LEVELS. AFTER 48 HOURS OF TREATMENT, FLOW CYTOMETRY WAS UTILIZED TO MEASURE THE A1–40 LEVELS IN SHAPP CELLS THAT HAD BEEN EXPOSED TO VARIOUS DOSES OF TAT. (B) PERCENTAGE QUANTIFICATION OF POSITIVE CELLS



FIG. 6: COC CAUSES AN INTENSIFICATION IN A40 SECRETION. AS WITH HIV-1 TAT, AN ELISA AND FLOW CYTOMETRY STUDY PATTERN WERE EMPLOYED WITH NUMEROUSSTRENGTHS OF COC TO DETERMINE AN APPROPRIATE DOSE OF COC FOR ADDITIONAL INVESTIGATIONS. (A) COC PROMOTES THE SYNTHESIS OF A1–40. COC (0.1–10 M) INCREASED SECRETED A1–40, AND ONLY THE MATERIALS MAINTAINED WITH 0.1 M COC SHOWED A SIGNIFICANT RISE. (B) CELL VIABILITY IN COC-TREATED SAMPLES AS DETERMINED BY A CELLULAR TOXICITY ASSAY. (C) WHEN CONTRAST TO COC-ONLY PRESERVED SAMPLES, 2M WA CONSIDERABLY COMPACTED COC (0.1 M) AND DECREASED A1–40 LEVELS



FIG. 7: DOSAGE RESPONSE. (A) SCREENING COC (0.5–10 MM) INTENSIFICATIONS OF THE BETA-AMYLOIDSTAGES. (B) QUANTIFICATION DIAGRAM OF CELLS FOUND NOT SIGNIFICANT)

Tat and COC Produced an Enhancement in A β 40 Strength: The cells were incubated and stained continuously with the MAP2-specific antibody following 24 hrs.

By rinsing the cells, an additional anti-rabbit FITC-labeled antibody was used to stain them. In comparison to (C) SH-APP cells (COC exposed), which showed extensive dendritic(green arrows) and vacuoles incytoplasm, both of which are signs of stimulant stress, (A) SH-APP cell line (B) WA exposed cells investigated no abnormal dendritic thickening or beading.

(D) WA exposed COC cell line had less dendritic beading, straighter dendrites, and fewer cytoplasmic vacuoles, showing HIV-1-associated neurocognitive dysfunction (HAND) **Fig. 8.**



FIG. 8: IT'S COC AND TAT MIX. (A) TAT (50 NG/ML) AND COC (0.1 M) ENHANCE A1–40 LEVELS INDIVIDUALLY AND IN COMBINATION. THE CELLS WERE EXPOSED TO VARIOUS STRENGTHS OF TAT COC, AS WELL AS A COMBINATION OF BOTH, AND THE A1–40 LEVELS WERE DETERMINED USING FLOW CYTOMETRY. (B) QUANTIFICATION OF % POSITIVE CELLS (*P 0.05)

***In-vitro:* WA Overturns Amyloid Accumulates Caused by Tat and COC:** WA Reverses Amyloid Aggregates Caused by Tat and COC Immunocytochemistry tests demonstrated that WA reduced amyloid formation in SH-APP cells when contrasted to without treated group SH-APP cell line. The cells were produced for 24 hrs in eight well microscope photographs before being exposed with Tat+/WA and COC+/WA after 48 hours, with fresh media added to the control wells.

The cells were then received, frozen, and labeled with a 1:100 β-amyloid 1–40 primary antibody as well as a secondary GFP antibody (1:100). Whenever the Tat + WA and COC + WA microscopic compartments were compared with the control well, we found that the cells treated with Tat and COC displayed high indications of amyloid-beta accumulation, which were decreased by WA administration **Fig. 9A–G.**



FIG. 9: WABLOCKS THE HIV-1 TAT PRODUCED SYNTHESIS. HIV-1 TAT (50 NG/ML; C), COC (0.1 M; E) +/ WA (2 M; D, F) MEDICATED SH-APP CELLS WERE IN CONTRAST TO CONTROL GROUP (A) ALONE WA TREATMENT CELLS. (B). THE SAMPLES WERE TREATED AND STAINED NIGHT WITH ANTI-HUMAN A40 FOLLOWING 24 HOURS. AFTER RINSING THE CELLS, THEY WERE STAINED WITH AN ADDITIONAL ANTI-RABBIT FITC-ANTIBODY. KEYENCE'S ALL-IN-ONE MICROSCOPE (10) WAS USED TO TAKE THE PHOTOGRAPHS. BOTH TAT AND COC-INDUCED AB-SECRETION WERE CONSIDERABLY DECREASED BY WA (N = 3). IMAGEJ SOFTWARE WAS USED TO QUANTIFY THE FLORAL INTENSITY OF SUCH STAINED CELLS

WA Decreases COC Persuaded Neurotoxicity: The unfavorable actions of COC in the SH-APP cell line and the influence of WA on the neuronal cell morphological structure were also investigated.

The deleterious actions of COC on SH-APP cells and the influence of WA on neuronal cell morphology were investigated using immunofluorescence imagination. Before labeling with the MAP2 primary antibody, SH-APP cell cultures were grown for 48 hours on the eight well imaging slides.

In cells exposed to COC for the next two days, more dendritic beading (showed by yellow arrows) and vacuoles inthe cytoplasm were detected **Fig. C**.

There was minimal aberrant edging or clotting in the dendrites of control cells (SH-APP cell line) **Fig. 10A** & WA exposed (SH-APP) cells **Fig. B.** We noticed less dendritic edging and more prominent dendrites linking to the dendrites after treatment with WA.

After treatment with WA, we discovered reduced dendritic edging and more prominent dendrites connecting to neuronal cells that were COC exposed **Fig. D**.

We also found fewer vacuoles of cytoplasm in the WA-exposed cells. This reveals that COC causes neuronal damage by creating a stressful environment in the cell culture **Fig. 10.**



FIG. 10: DENDRITIC BEADING AND CYTOPLASMIC VACUOLES ARE REVERSED BY WA. COC (0.1 M) +/WA (2 M) WAS USED TO TREAT SH-APP CELLS.AFTER 24 HOURS, THE CELLS WERE TREATED AND STAINED OVERNIGHT WITH THE MAP2 ANTIBODY. AFTER WASHING THE CELLS, THEY WERE STAINED WITH AN ANTI-RABBIT FITC-LABELED SECONDARY ANTIBODY. IN CONTRAST TO (C) SH-APP CELLS (COC EXPOSED), WHICH DISPLAYED CONSIDERABLE DENDRITIC BEADING (GREEN ARROWS) AND VACUOLES IN CYTOPLASM, A SYMPTOM OF DRUG-INDUCED STRESS, (A) SH-APP CELLS (B) WA EXPOSED CELLS - NO ABERRANT DENDRITIC BEADING, NO THICKENING. (D) WA-EXPOSED COC CELLS DISPLAYED LESS DENDRITIC BEADING, LONGER DENDRITES, AND FEW CYTOPLASMIC VACUOLES, INDICATING HIV-1-RELATED NEUROCOGNITIVE DISORDERS THAT WERE EXPOSED TO COC FIG. D

DISCUSSION: This research, which focuses on the degeneration of the neurons instigated by old aging or virus infections, is critical right now. The key aspect contributing to neuron degeneration is accretion in the CNS [11]. The summary of HAART has a long life, providing the best chance for phase-related symptoms to improve in patients [15]. There are recently obtain able medicines that are contraindicated with A buildup. The Memantine NMDA receptor blocker, for example, assists in healing damaged neurons though not in the overall therapy of neurological disorders [16].

Curcuminoid, taken from the word roots of the herbal Curcuma longa plant, is another great medication planned for its neuroprotective, anti-inflammatory, antineoplastic, and antioxidant qualities [17]. There is currently no specific treatment available for neurological symptoms resembling Alzheimer's. As a result, our research focuses on the neuroprotective agent WA, which protects neurons against Aβ-induced neurotoxicity. According to the findings, of inaccessible cell cultures, WA lowers the quantities of released A. while preventing cytotoxicity. Because human cell neuroblastoma showed strong development in the occurrence of WA, our microscopic tests validate the protective character of WA. We discovered that WA activity condensed cytoplasmic vacuoles and dendritic beading in SH-APP cells, indicating that WA is acting defensively. Additional research reveals that administering *W. somnifera* with the whole root extract increases neuronal fitness by stimulating *in-vitro* dendritic development, which supports our idea [18, 19].

Furthermore, we concentrated on the small energetic mediety of the extraction of the Withania root, called WA, in an *in-vitro* examination of SH-APP cells, which neutralizes released A levels. Our backresearch looked at the ashwagandha portion extracted from the roots of *W. Somnifera*. Tat [20] is well-known [12]. To counteract neuronal cells, we determined the properties of ashwagandha *in-vitro*. When ASH was compared to unprocessed panels, it showed a significant decrease in A, indicating a role for ASH as an anti-amyloid [21]. Ashwagandha (ASH) is proficient in dropping hidden A; this type of ASH's efficiency in CNS enters through the BBB due to a large moiety. As a result, effective medication transit into the CNS and enhanced bioavailability become a recurring problem. This

indicated that finding effective molecular mass particles with similar properties was critical. When the ASH molecule is disrupted, organized chromatographic analyses reveal the mechanism. We also needed to figure out what effect WA had on tempted Aβ production when HIV-1 Tat came into touch with it.

As a result, we looked at the influence of Tat protein (HIV-1) (Merino *et al.*, 2011) on Aβ release in the SH-APP cell line in neurons and discovered that A production was greatly boosted, according to findings in a cell line with recent studies that have discovered a role for Tat in enhanced Aβ release in neurons [22, 24]. The neurotoxin Tat protein show an increase in Aβ accumulation in the cell line study. Tat protein may have direct binding with WA, albeit how this occurs is unknown [7, 22].

Our IHC results, demonstrating a solid concentration of Aβ in the medium of the cell after exposure to the Tat protein (50 ng/ml), back up this theory. We discovered increased amounts of A in Tat-treated samples in our human A40 ELISA study. This leads us to conclude that Tat is extremely neurotoxic and can interact with A, so increasing the cell system's overall toxicity and stimulating the release and aggravation of A. The Tat protein from HIV-1 interacts directly with the A peptide, generating excessive A aggregation and neurotoxicity [20].

Furthermore, Cocaine addiction is one of the most often abused narcotics among HIV-positive people, and it has been associated with a rise in the severity of neurocognitive deficits in those who use it [25, 27]. Furthermore, among HIV-positive patients and the elderly, the percentage of drug addicts is quite high. Since the start of the HIV/AIDS pandemic, drug use and dependence have been connected. In 2015, those who take drugs contributed to around 6% of HIV diagnoses in 2018 (CDC). The COC has been associated with a rise in HIV neuronal disease, the pathways that cause this are unknown. We detected elevated amounts of Aβ generation by COC in this investigation for the first time, elucidating the mechanism. *In-vitro*, we found that COC impacts neuronal morphology and connections, as well as aggregation in SH-APP cells, in our Immunocytochemistry investigations. This confirms that COC has a deleterious effect on neuronal cells, which contributes to increased amyloid formation. HIV-1 (Tat) is extremely injurious to the nervous system. These data imply that COC injection into the peritoneal cavity of rats causes hippocampus, hyperphosphorylation of tau and neurofilament, hence circuitously associating to Aβ toxicity in neurons [28].

The data point to a relationship between Cocaine addiction and neurofibrillary degeneration. As a result, we show that COC, when combined with Tat protein, enhances Aβ release in cell line study. According to the results, COC and HIV-1 Tat produce neural dysfunction by enhancing Aβ release and changing the structure of neurons and communication, resulting in cellular damage and neuronal dysfunction.

Furthermore, aggregation and confession in the HIV-associated patient's brain cause neurons related disorders, which exacerbates the effects of aging and dementia [28]. Furthermore, the absence of direct drugs that trace neuronal issues is the primary motive for developing WA. Furthermore, pharmacological shortcomings such as insufficient physical chemistry, limited absorption, undesirable pharmacokinetic features, instability, and toxicity lead to medicine rejection. This emphasizes the relevance of complementary and alternative medicine and nanomedicine.

As a result, we'll apply nanotechnology-assisted ways to discourse the restriction or incapacity of pharmaceuticals to penetrate the barrier of the brain, wherein our produced medicine magneto-liposomes would be capable of transmigrating over the BBB [29, 30]. To summarize, developing and discovering drugs that target and block Aβ aggregation and secretion and the aggregation of other proteins is crucial.

To counteract their synergistic activity in neurodegenerative diseases, it is dangerous to discover and uncover materials that precisely inhibit Aβ aggregation and secretion, as well as the linking between HIV-Tat 1 and A. When added with A-targeting treatments like therapy of the immune system, these strategies may lessen, if not eliminate, A-associated toxic effects. The efficacy of animal study and delivery of drug mechanism research is needed to examine WA's health benefit

role in neuronal diseases such as HIV-associated cognition impairments and Alzheimer's disease.

ACKNOWLEDGEMENTS: Nil

CONFLICTS OF INTEREST: Our research revealed new stages of drug proficiency, contradicting the novelist's state that the examination was focused on the absence of potentially profitable or monetary interactions, which may be viewed as a probable battle of awareness.

REFERENCES:

1. Oguntibeju O: Quality of life of people living with HIV and AIDS and antiretroviral therapy. HIV/AIDS - Res Palliat Care. Published online August 2012:117. doi:10.2147/HIV.S32321
2. Saylor D, Dickens AM and Sacktor N: HIV-associated neurocognitive disorder - Pathogenesis and prospects for treatment. Nat Rev Neurol 2016; 12(4): 234-248. doi:10.1038/nrneurol.2016.27
3. Koppel BS, Wormser GP, Tuchman AJ, Maayan S, Hewlett D and Daras M: Central nervous system involvement in patients with acquired immune deficiency syndrome (AIDS). Acta Neurol Scand 2009; 71(5): 337-353. doi:10.1111/j.1600-0404.1985.tb03211.x
4. Dorszewska J, Prendecki M, Oczkowska A, Dezor M and Kozubski W: Molecular Basis of Familial and Sporadic Alzheimer's Disease. Curr Alzheimer Res 2016; 13(9): 952-963. doi:10.2174/1567205013666160314150501
5. Snider WD, Simpson DM, Nielsen S, Gold WMJ, Metroka CE and Posner JB: Neurological complications of acquired immune deficiency syndrome: Analysis of 50 patients. Ann Neurol 1983; 14(4): 403-418. doi:10.1002/ana.410140404
6. Ghosh AK, Gemma S and Tang J: β-Secretase as a therapeutic target for Alzheimer's disease. Neurotherapeutics 2008; 5(3): 399-408. doi:10.1016/j.nurt.2008.05.007
7. Cheignon C, Tomas M, Bonnefont-Rousselot D, Faller P, Hureau C and Collin F: Oxidative stress and the amyloid beta peptide in Alzheimer's disease. Redox Biol 2018; 14: 450-464. doi:10.1016/j.redox.2017.10.014
8. Arimon M, Takeda S, Post KL, Svirsky S, Hyman BT and Berezovska O: Oxidative stress and lipid peroxidation are upstream of amyloid pathology. Neurobiol Dis 2015; 84: 109-119. doi:10.1016/j.nbd.2015.06.013
9. Barage SH and Sonawane KD: Amyloid cascade hypothesis: Pathogenesis and therapeutic strategies in Alzheimer's disease. Neuropeptides 2015; 52: 1-18. doi:10.1016/j.npep.2015.06.008
10. Martínez-Bonet M, Muñoz-Fernández MÁ and Álvarez S: HIV-1 increases extracellular amyloid-beta levels through neprilysin regulation in primary cultures of human astrocytes. J Cell Physiol 2019; 234(5): 5880-5887. doi:10.1002/jcp.26462
11. Mirjalili M, Moyano E, Bonfill M, Cusido R and Palazón J: Steroidal Lactones from Withania somnifera, an Ancient Plant for Novel Medicine. Molecules 2009; 14(7): 2373-2393. doi:10.3390/molecules14072373
12. Choi BY and Kim BW: Withaferin-A Inhibits Colon Cancer Cell Growth by Blocking STAT3 Transcriptional Activity. J Cancer Prev 2015; 20(3): 185-192. doi:10.15430/JCP.2015.20.3.185
13. Mohan R and Bargagna-Mohan P: The Use of Withaferin A to Study Intermediate Filaments. In 2016; 187-218. doi:10.1016/bs.mie.2015.09.025
14. Rah B, Amin H and Yousuf K: A Novel MMP-2 Inhibitor 3-azidowithaferin A (3-azidoWA) Abrogates Cancer Cell Invasion and Angiogenesis by Modulating Extracellular Par-4. Nie D, ed. PLoS One 2012; 7(9): 44039. doi:10.1371/journal.pone.0044039
15. Heaton RK, Franklin DR and Ellis RJ: HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors. J Neurovirol 2011; 17(1): 3-16. doi:10.1007/s13365-010-0006-1
16. van Marum RJ: Current and future therapy in Alzheimer's disease. Fundam Clin Pharmacol 2008; 22(3): 265-274. doi:10.1111/j.1472-8206.2008.00578.x
17. Sharma RA, Steward WP, Gescher AJ. Pharmacokinetics and Pharmacodynamics of Curcumin. In: 2007; 453-470. doi:10.1007/978-0-387-46401-5_20
18. Zhao J, Nakamura N, Hattori M, Kuboyama T, Tohda C and Komatsu K: Withanolide Derivatives from the Roots of With*ania somnifera* and Their Neurite Outgrowth Activities. Chem Pharm Bull 2002; 50(6): 760-765. doi:10.1248/cpb.50.760
19. Tohda C, Kuboyama T, Komatsu K. Dendrite extension by methanol extract of Ashwagandha (roots of *Withania somnifera)* in SK-N-SH cells. Neuroreport. 2000; 11(9): 1981-1985. doi:10.1097/00001756-200006260-00035
20. Hategan A, Bianchet MA and Steiner J: HIV Tat protein and amyloid-β peptide form multifibrillar structures that cause neurotoxicity. Nat Struct Mol Biol 2017; 24(4): 379-386. doi:10.1038/nsmb.3379
21. Kurapati KRV, Atluri VSR, Samikkannu T and Nair MPN: Ashwagandha (*Withania somnifera*) Reverses β-Amyloid1-42 Induced Toxicity in Human Neuronal Cells: Implications in HIV-Associated Neurocognitive Disorders (HAND). Lakshmana MK, ed. PLoS One 2013; 8(10): 77624. doi:10.1371/journal.pone.0077624
22. Aksenov MY, Aksenova MV, Mactutus CF and Booze RM: HIV-1 protein-mediated amyloidogenesis in rat hippocampal cell cultures. Neurosci Lett 2010; 475(3): 174-178. doi:10.1016/j.neulet.2010.03.073
23. Giunta B, Hou H and Zhu Y: HIV-1 Tat contributes to Alzheimer's disease-like pathology in PSAPP mice. Int J Clin Exp Pathol 2009; 2(5): 433-443. http://www.ncbi.nlm.nih.gov/pubmed/19294002
24. Rempel HC and Pulliam L: HIV-1 Tat inhibits neprilysin and elevates amyloid β. AIDS 2005; 19(2): 127-135. doi:10.1097/00002030-200501280-00004
25. Gannon P, Khan MZ and Kolson DL: Current understanding of HIV-associated neurocognitive disorders pathogenesis. Curr Opin Neurol 2011; 24(3): 275-283. doi:10.1097/WCO.0b013e32834695fb
26. Buch S, Yao H and Guo M: Cocaine and HIV-1 Interplay in CNS: Cellular and Molecular Mechanisms. Curr HIV Res 2012; 10(5): 425-428. doi:10.2174/157016212802138823
27. Esiri MM, Biddolph SC and Morris CS: Prevalence of Alzheimer plaques in AIDS. J Neurol Neurosurg Psychiatry 1998; 65(1): 29-33. doi:10.1136/jnnp.65.1.29
28. Liu SJ, Fang ZY, Yang Y, Deng HM and Wang JZ: Alzheimer-like phosphorylation of tau and neurofilament induced by cocaine *in-vivo*. Acta Pharmacol Sin 2003; 24(6): 512-518. http://www.ncbi.nlm.nih.gov/pubmed/12791176

29. Ding H, Sagar V and Agudelo M: Enhanced blood–brain barrier transmigration using a novel transferrin embedded fluorescent magneto-liposome nanoformulation. Nanotechnology 2014; 25(5): 055101. doi:10.1088/0957-4484/25/5/055101

30. Nath A, Psooy K and Martin C: Identification of a human immunodeficiency virus type 1 Tat epitope that is neuroexcitatory and neurotoxic. J Virol 1996; 70(3): 1475-1480. doi:10.1128/jvi.70.3.1475-1480.1996

How to cite this article:
Sharma S, Vineylather, Sharma V and Ram C: Withaferin a: an exploration of tropane alkaloid associated neurological dysfunction by conquering a beta protein. Int J Pharm Sci & Res 2023; 14(10): 5074-86. doi: 10.13040/IJPSR.0975-8232.14(10).5074-86.